Export Partners » Products » Macrostip Linea
Available formats
MACROSTIP® is a medical device based on Macrogol 4000. Macrostip® is indicated for the treatment of chronic constipation; Faecaloma (situation of rebellious constipation with stool accumulation at the rectum level and/or colon level confirmed by physical examination of abdomen and rectum); treatment of constipation with episodic or chronic colic; situations requiring colon cleansing (sachets).
MACROSTIP® psyllium is a medical device based on Macrogol 4000 and Psyllium fiber.
Solution
Adults and children over 8 years: 20-40 ml per day; Children between 4 and 7 years: 15-30 ml per day; Children between 2 and 3 years: 10-15 ml per day; infants between 6 months and 7 years (body weight>7kg): 5-10 ml per day
Sachets (constipation): Elderly, adults, and children from 12 years: 1 sachet (10 g) 1-3 times a day; Children from 7 to 17 years: half sachet (5 g) 2 times a day; Children from 3 to 6 years: half sachet (5 g) 1 time a day
Sachets (colon cleansing): Adults: 23 sachets dissolved in 4 liters of still water to be taken in a single dose, the afternoon before the exam, or split into two doses, 2 liters the evening before the exam and 2 liters the morning of the exam.
MACROSTIP® psyllium: Adults: 2 sachets per day, preferably morning and evening; Children and teenagers from 6 to 14 years: 1 sachet per day.
Chronic constipation is a common functional gastrointestinal disorder, a condition frequently encountered in clinical practice, both in specialty office (e.g., gastroenterology, geriatrics) and in general medicine.
About 30% of the general population experiences problems with constipation during lifetime, with elderly people and women being mostly affected. Chronic constipation has considerable impact on health and quality of life.
Lifestyle changes (light physical activity, increase the intake of fluids, fruits and vegetables) do not usually meet with complete patient satisfaction. Other treatments include different types of laxatives. Of these, osmotic laxatives appear one of the most effective and are, therefore, frequently prescribed.
One of the conceptual aspects that makes constipation a clinical entity arduous to be managed is the absence of a generally accepted definition of the disease. The traditional criterion refers to a limited number of weekly evacuations, although patients mostly complain of symptoms associated with difficult stool passage, such as evacuation of hard or lumpy stools or the need of excessive efforts and/or manipulation during defecation.
From a pathogenetic point of view, chronic constipation may itself be the disease, such as in primary forms, or be part of a complex clinical picture, as in secondary forms. This distinction is crucial for a proper management of constipation.
Secondary forms of constipation can be caused by several systemic diseases as well as by some drugs of common use.
De Giorgio R, Ruggeri E, Stanghellini V, Eusebi LH, Bazzoli F, Chiarioni G. Chronic constipation in the elderly: a primer for the gastroenterologist. BMC Gastroenterol. 2015 Oct 14;15:130. doi: 10.1186/s12876-015-0366-3. PMID: 26467668; PMCID: PMC4604730.
Fonte:
De Giorgio R, Ruggeri E, Stanghellini V, Eusebi LH, Bazzoli F, Chiarioni G. Chronic constipation in the elderly: a primer for the gastroenterologist. BMC Gastroenterol. 2015;15:130. Published 2015 Oct 14.
Join Us at CPhI Milan 2024 in Rho Fiera, one of the biggest pharma event of the year!
Visit our booth #14F49 in Hall 14 from Tuesday, October 8th till Thursday, October 10th.
Don’t miss out on the opportunity to connect and meet with us for new business opportunities!
This information is exclusively dedicated to B2B communications for the worldwide distribution of our products.
Do you declare to be a business partner?